Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1371/journal.pmed.1003656 http://scihub22266oqcxt.onion/10.1371/journal.pmed.1003656 34228725!8291755!34228725     free     free     free Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       PLoS+Med 2021 ; 18 (7): e1003656 Nephropedia Template TP {{tp|p=34228725|t=2021. SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants |pdf=|usr=}}{{34228725}} gab.com Text SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants JO: PLoS Med http://www.kidney.de/pget.php?&tw=1&pmid=34228725 #FOAvip The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antibody neutralization response and its evasion by emerging viral variants and variant of concern (VOC) are unknown, but critical to understand reinfection risk and breakthrough infection following vaccination. Antibody immunoreactivity against SARS-CoV-2 antigens and Spike variants, inhibition of Spike-driven virus-cell fusion, and infectious SARS-CoV-2 neutralization were characterized in 807 serial samples from 233 reverse transcription polymerase chain reaction (RT-PCR)-confirmed Coronavirus Disease 2019 (COVID-19) individuals with detailed demographics and followed up to 7 months. A broad and sustained polyantigenic immunoreactivity against SARS-CoV-2 Spike, Membrane, and Nucleocapsid proteins, along with high viral neutralization, was associated with COVID-19 severity. A subgroup of "high responders" maintained high neutralizing responses over time, representing ideal convalescent plasma donors. Antibodies generated against SARS-CoV-2 during the first COVID-19 wave had reduced immunoreactivity and neutralization potency to emerging Spike variants and VOC. Accurate monitoring of SARS-CoV-2 antibody responses would be essential for selection of optimal responders and vaccine monitoring and design. Twit Text FOAVip SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants ????PLoS Med http://www.kidney.de/pget.php?&tw=1&pmid=34228725 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34228725 #FOAvip English Wikipedia <ref>{{Cite pmid|34228725}}</ref> SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants #MMPMID34228725 Tea F; Ospina Stella A; Aggarwal A; Ross Darley D; Pilli D; Vitale D; Merheb V; Lee FXZ; Cunningham P; Walker GJ; Fichter C; Brown DA; Rawlinson WD; Isaacs SR; Mathivanan V; Hoffmann M; Pohlman S; Mazigi O; Christ D; Dwyer DE; Rockett RJ; Sintchenko V; Hoad VC; Irving DO; Dore GJ; Gosbell IB; Kelleher AD; Matthews GV; Brilot F; Turville SG PLoS Med 2021[Jul]; 18 (7): e1003656 PMID34228725show ga The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antibody neutralization response and its evasion by emerging viral variants and variant of concern (VOC) are unknown, but critical to understand reinfection risk and breakthrough infection following vaccination. Antibody immunoreactivity against SARS-CoV-2 antigens and Spike variants, inhibition of Spike-driven virus-cell fusion, and infectious SARS-CoV-2 neutralization were characterized in 807 serial samples from 233 reverse transcription polymerase chain reaction (RT-PCR)-confirmed Coronavirus Disease 2019 (COVID-19) individuals with detailed demographics and followed up to 7 months. A broad and sustained polyantigenic immunoreactivity against SARS-CoV-2 Spike, Membrane, and Nucleocapsid proteins, along with high viral neutralization, was associated with COVID-19 severity. A subgroup of "high responders" maintained high neutralizing responses over time, representing ideal convalescent plasma donors. Antibodies generated against SARS-CoV-2 during the first COVID-19 wave had reduced immunoreactivity and neutralization potency to emerging Spike variants and VOC. Accurate monitoring of SARS-CoV-2 antibody responses would be essential for selection of optimal responders and vaccine monitoring and design. |Adult[MESH] |Antibodies, Neutralizing/*immunology[MESH] |Antibodies, Viral/immunology[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Nucleocapsid Proteins/immunology[MESH]SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by(epmc).pdf DeepDyve Pubget Overpricing